Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

MXCT vs BWAY: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BWAY Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 7–3 Matrix Metrics)

BWAY Overall Winner 6-Pillar Tally: MXCT 1 – 5 BWAY Matrix Metrics: MXCT 3 – 7 BWAY

As of Nov 20, 2026, Brainsway Ltd. (BWAY) is the stronger overall head-to-head candidate over MaxCyte, Inc. (MXCT) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MXCT carries a Unified Composite Score of 41.7/100 (SELL) at $1.37 (N/M Forward P/E, -85.5% operating margin), whereas BWAY carries 31.8/100 (SELL) at $8.48 (17.0x Forward P/E, 12.5% operating margin).

  • Composite vs. Pillar Nuance: While MXCT currently prints a higher short-term Unified Composite Score (41.7/100 SELL vs. BWAY 31.8/100 SELL), BWAY captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (12.5% vs. -85.5% operating margin) and revenue trajectory (+35.4% vs. +48.7% YoY).
  • Defensive Composite Rating Caution: Although BWAY compares more favorably head-to-head, both MXCT (41.7/100 SELL) and BWAY (31.8/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: MXCT trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 55.3); meanwhile BWAY is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 27.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MXCT vs BWAY
MXCT NASDAQ
MaxCyte, Inc. Common Stock
Services-Commercial Physical & Biological Research
$1.37
+7.03% 1D
Market Cap $132.2M
TTM Revenue $34M
Forward P/E N/M
Beta / 30D Vol 1.19β · 96% Vol
Unified Composite Score
41.7 / 100 SELL
Tech 46.0 Fund 52.0 Flow 62.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (2.1% over 20 days), RSI 55
RSI-14: 55.3 · SMA20: $1.36 · SMA50: $1.25
BWAY NASDAQ Head-to-Head Winner
Brainsway Ltd. American Depositary Shares
Surgical & Medical Instruments & Apparatus
$8.48
-2.86% 1D
Market Cap $351.4M
TTM Revenue $108M
Forward P/E 17.0x
Beta / 30D Vol 1.84β · 66% Vol
Unified Composite Score
31.8 / 100 SELL
Tech 25.0 Fund 43.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -12.0%), weak momentum, RSI 28
RSI-14: 27.7 · SMA20: $10.57 · SMA50: $11.74

6-Pillar Scorecard Institutional Category Breakdown (MXCT 1 – 5 BWAY)

Columns: Metric · MXCT · BWAY
1. Valuation Multiples BWAY
Forward P/E N/M 17.0x
Trailing P/E N/M 36.4x
PEG Ratio N/M N/M
EV / Revenue 3.9x 3.3x
2. Growth & Scale BWAY
Revenue Growth (YoY) +48.7% +35.4%
Earnings Growth (YoY) +0.0% +59.8%
TTM Revenue (USD) $34M $108M
Market Cap $132.2M $351.4M
3. Profitability & Quality BWAY
Gross Margin 81.0% 75.3%
Operating Margin -85.5% 12.5%
Net Profit Margin -81.4% 15.6%
Return on Equity (ROE) -16.9% 12.8%
4. Balance Sheet & Cash Flow BWAY
Cash Generation (TTM) -$24M $15M EBITDA
Cash Flow Margin -69.2% 14.0% EBITDA Mgn
Net Cash / Leverage $2.2M Net Debt (0.11x D/E) $1.97 Book/Sh · 12.8% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MXCT
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 111.0% (77th %ile)
Put/Call OI Skew N/A Thin ADR Chain
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat BWAY
OpEx & R&D Intensity N/A 62.8% of Rev ($68M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MXCT (3) vs BWAY (7)
Institutional Metric MXCT BWAY Criterion Row Edge
Market Capitalization
Scale
$132.2M $351.4M Larger Scale BWAY
Trailing P/E Ratio
Valuation
N/M 36.4x Lower Multiple BWAY
Forward P/E Ratio
Valuation
N/M 17.0x Lower Multiple BWAY
Revenue Growth (YoY)
Growth
+48.7% +35.4% Higher Growth MXCT
Operating Margin (TTM)
Profitability
-85.5% 12.5% Higher Margin BWAY
Net Profit Margin
Profitability
-81.4% 15.6% Higher Margin BWAY
Return on Equity (ROE)
Capital Efficiency
-16.9% 12.8% Higher ROE BWAY
52-Week Range Position
Momentum
63% ($1–$2) 0% ($8–$27) Stronger Trend MXCT
Beta / 30D Volatility
Risk Regime
1.19β · 96% Vol 1.84β · 66% Vol Lower Realized Risk BWAY
Unified Institutional Score
Composite Signal
41.7 / 100 (SELL) 31.8 / 100 (SELL) Higher Composite MXCT
Trailing 12M Revenue (USD)
Operating Scale
$34M $108M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
81.0% 75.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.9x EV/Rev N/M PEG · 3.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$24M ($2.2M Net Debt (0.11x D/E)) $15M EBITDA ($1.97 Book/Sh · 12.8% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MXCT +21.67 pp
MXCT: -4.2% · BWAY: -25.87%
3M Horizon MXCT +38.8 pp
MXCT: -1.44% · BWAY: -40.24%
6M Horizon MXCT +75.57 pp
MXCT: +31.73% · BWAY: -43.84%
1Y Horizon MXCT +24.47 pp
MXCT: -19.41% · BWAY: -43.88%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MXCT vs BWAY. Trailing 12-month operating profitability (MXCT -85.5% vs BWAY 12.5%) and valuation multiples (MXCT N/M vs BWAY 17.0x Forward P/E) are benchmarked directly in Pillar 4 below.

MXCT ADR TTM Benchmark FX-Normalized USD
TTM Revenue$34M
Gross Margin81.0%
Op. Margin-85.5%
ROE / Fwd P/E-16.9% · N/M
BWAY ADR TTM Benchmark FX-Normalized USD
TTM Revenue$108M
Gross Margin75.3%
Op. Margin12.5%
ROE / Fwd P/E12.8% · 17.0x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MXCT UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact MXCT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BWAY UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 111.0%
IV Percentile 77th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BWAY Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MXCT Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $132.2M market capitalization and -85.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
BWAY Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $351.4M market capitalization and 12.5% operating margin.
OpEx & R&D Reinvestment 62.8% of Rev ($68M)
90D Engineering Disclosures 0 Published

Investor FAQ MXCT vs BWAY Key Questions & Quantitative Answers

As of Nov 20, 2026, Brainsway Ltd. (BWAY) is the stronger overall head-to-head candidate over MaxCyte, Inc. (MXCT) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MXCT carries a Unified Composite Score of 41.7/100 (SELL) at $1.37 (N/M Forward P/E, -85.5% operating margin), whereas BWAY carries 31.8/100 (SELL) at $8.48 (17.0x Forward P/E, 12.5% operating margin). Composite vs. Pillar Nuance: While MXCT currently prints a higher short-term Unified Composite Score (41.7/100 SELL vs. BWAY 31.8/100 SELL), BWAY captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (12.5% vs. -85.5% operating margin) and revenue trajectory (+35.4% vs. +48.7% YoY). Defensive Composite Rating Caution: Although BWAY compares more favorably head-to-head, both MXCT (41.7/100 SELL) and BWAY (31.8/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: MXCT trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 55.3); meanwhile BWAY is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 27.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

BWAY leads the Growth & Scale pillar: MXCT posts +48.7% YoY revenue growth and +0.0% YoY earnings growth on $34M TTM revenue (81.0% gross margin, -85.5% operating margin), compared with BWAY at +35.4% YoY revenue growth and +59.8% YoY earnings growth on $108M TTM revenue (75.3% gross margin, 12.5% operating margin). On trailing 12-month operating scale, MXCT generates $34M in USD-normalized revenue versus $108M for BWAY. In operating R&D and SG&A reinvestment, MXCT deploys N/A (0 90-day corporate R&D disclosures) versus 62.8% of Rev ($68M) (0 disclosures) for BWAY.

BWAY screens cheaper on headline valuation multiples. MXCT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.9x EV/Revenue (-69.2% FCF margin), whereas BWAY trades at 17.0x Forward P/E, 36.4x Trailing P/E, N/M PEG, and 3.3x EV/Revenue (14.0% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MXCT (-16.9% ROE) versus BWAY (12.8% ROE) capital efficiency.

In options market volatility and institutional positioning, MXCT carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.19β · 96% Vol realized risk). By comparison, BWAY carries 111.0% implied volatility (77th %ile, Elevated (60th–80th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.84β · 66% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.